Lung
cancer is a malignant lung tumor, which is characterized by
uncontrolled division and growth of cells in the lungs. The ability
of lungs to provide oxygen into the bloodstream decreases with
increasing size of tumor. The lung carcinoma is classified as,
non-small cell and small cell lung cancer and originates from the
epithelial cells. Lung cancer has the highest mortality rate
globally, where exposure to asbestos, cigarette and pipe smoking is
attributed the foremost reason. Major symptoms of lung cancer
includes, body mucus, chest pain, weight loss, and coughing.
Chemotherapy, immunotherapy, vaccines, and radiation therapy are the
common lung cancer treatments.
Ask
for Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/702
Rising
incidences of non-small cell lung cancer is expected to drive the
global lung cancer therapeutics market
According
to the World Health Organization estimates in 2017, 1.8 million new
lung cancer cases were diagnosed in 2012 globally accounting for the
leading causes of morbidity and mortality. The launch of innovative
radiation therapies, premium priced drugs, and rising incidences of
non-small cell lung cancer (NSCLC) are the major driving factors for
the growth of the market. The rising demand for targeted therapies is
likely to have an optimistic impact over the lung cancer therapeutics
market in the forecast period. Targeted therapies block the growth by
targeting cancer-specific proteins, cells, and tissues that lead to
cancer survival and division, without damaging the healthy cells.
They are also proved to have higher efficiency over conventional
therapies like platinum-based chemotherapy, surgical resection, and
radiation therapy.
Higher
carcinoma lung population dominates the lung cancer therapeutics
market in North America
Regional
segmentation of the lung cancer therapeutics market by Coherent
Market Insights comprises North America, Europe, Asia-Pacific, Latin
America and Middle East, and Africa. According to the American Cancer
Society estimates of 2017, approximately 195,000 people are suffering
from NSCLC every year in the U.S. where, the number of deaths from
NSCLC is recorded to be around 135,000, thus increasing the demand
for lung cancer therapeutics in North America.
New
product launches with higher efficiency forms a major growth strategy
of market players
The
key players operating the lung cancer therapeutics market are Pfizer,
Celgene, F. Hofmann-La Roche, AstraZeneca and Eli Lilly. The key
players adopt various strategies such as, development of efficient
drugs, acquisition and mergers, geographical expansion and major
investment in research and development to maintain their position in
the market. Other prominent vendors include ARIAD Pharmaceuticals,
OSE Immunotherapeutics, Novartis, Bristol-Myers Squibb, OncoGeneX.
Lung
Cancer Therapeutics Market Taxonomy -
The
global lung cancer therapeutics market is segmented on the basis of
therapy, distribution channel, and geography
On
the basis of therapy, the global lung cancer therapeutics market is
segmented into:
-
Chemotherapy
-
Gemzar
-
Alimta
-
Paraplatin
-
Taxotere
-
Navelbine
-
Targeted therapy
-
Avastin
-
Tarceva
-
Iressa
-
Gilotrif
-
Radiotherapy
-
Systemic Radiotherapy
-
External Beam Radiotherapy
-
Internal Radiotherapy
For
More Information, Browse Full Report Here:
https://www.coherentmarketinsights.com/ongoing-insight/lung-cancer-therapeutics-market-702
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment